# IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1)

**Last Updated:** December 4, 2025
**OCEBM Evidence Level:** 5 (Animal studies + mechanism-based reasoning)
**Risk Profile:** HIGH (Epidemiologically confirmed cancer association)

---

## What Is This?

IGF-1 LR3 is a souped-up version of insulin-like growth factor that bodybuilders use for muscle growth. It's modified to last 20-30 hours (vs 15 minutes for natural IGF-1) and is 2-3x more potent. **However, the cancer risk is real and epidemiologically proven** — a study of 400,000 people confirmed that elevated IGF-1 increases colorectal, breast, prostate, and thyroid cancer risk. It also causes dangerous hypoglycemia. People lacking IGF-1 signalling (Laron syndrome) have dramatically reduced cancer rates — providing genetic proof of this risk.

---

## Categories

`Muscle & Performance` · `GH Axis`

---

## Glossary

| Term | Meaning |
|------|---------|
| OCEBM | Oxford Centre for Evidence-Based Medicine — rates evidence quality |
| IGF-1R | IGF-1 Receptor — the protein that IGF-1 binds to activate cell growth |
| PI3K/Akt | A cell survival signalling pathway often hijacked by cancer |
| MAPK | Mitogen-Activated Protein Kinase pathway — promotes cell division |
| IGFBP | IGF Binding Proteins — normally keep 99% of IGF-1 inactive; LR3 evades these |
| Hypoglycemia | Dangerously low blood sugar |
| Laron syndrome | A genetic condition with no functional IGF-1 signalling — these people rarely get cancer |
| WADA | World Anti-Doping Agency — prohibits this substance in sport |
| VEGF | Vascular Endothelial Growth Factor — promotes blood vessel formation (tumour angiogenesis) |

---

## Key Specifications

| Property | Value |
|----------|-------|
| Type | Modified growth factor |
| Length | 83 amino acids |
| Molecular Weight | ~9,200 Da |
| Modification | Arg3 substitution + 13 AA N-terminal extension |
| Half-life | 20-30 hours (vs 15 min native IGF-1) |
| Potency | 2-3x native IGF-1 |
| IGFBP Binding | Very low (vs 99% bound for native) |
| FDA Status | Not approved |
| WADA Status | Banned |

---

## Mechanism of Action

IGF-1 LR3 functions through direct activation of the IGF-1 receptor, triggering two parallel signaling cascades that drive both its anabolic effects and its oncogenic risk. The PI3K/Akt pathway promotes cell survival and blocks apoptosis — the programmed cell death mechanism that normally eliminates damaged or potentially cancerous cells. Simultaneously, MAPK pathway activation drives proliferation, telling cells to divide and multiply. This dual action creates a powerful anabolic signal, but it also creates an environment where cancer cells can thrive.

What makes LR3 particularly potent — and particularly dangerous — is the structural modification that prevents binding to IGF binding proteins. In normal physiology, 99% of circulating IGF-1 is bound to IGFBPs, rendering it inactive. Only 1% circulates free and bioactive. LR3's modification evades this sequestration, meaning nearly 100% remains bioactive. This creates roughly 100-fold higher effective potency than equivalent doses of native IGF-1 — a pharmacological advantage that becomes a toxicological liability.

The extended 20-30 hour half-life compounds this issue. Native IGF-1 clears within 15 minutes, limiting exposure duration. LR3 maintains receptor activation for an entire day, providing sustained anabolic signaling but also sustained proliferative and anti-apoptotic signaling to any cancer cells present.

---

## Clinical Evidence

The evidence situation for IGF-1 LR3 presents a stark contrast: abundant mechanistic data supporting efficacy, epidemiological proof of cancer risk, and a complete absence of human safety trials.

### Epidemiological Evidence (Oxford, 2020)

The UK Biobank study analyzed approximately 400,000 participants, establishing causality through temporal sequence — IGF-1 was measured before cancer diagnosis, ruling out reverse causation. The confirmed associations include colorectal cancer, breast cancer, prostate cancer, and thyroid cancer (newly identified in this study). Potential associations emerged for melanoma and multiple myeloma.

The critical insight: this wasn't a retrospective study where cancer patients happened to have high IGF-1. This was prospective measurement showing that people with higher baseline IGF-1 subsequently developed cancer at higher rates. The causal arrow points from IGF-1 elevation to cancer development.

A separate J Clin Endocrinol Metab analysis (2023) examined mortality data, revealing a U-shaped curve where both very low and very high IGF-1 associated with increased all-cause mortality. The longevity sweet spot sits in the middle range — not the supraphysiological levels that IGF-1 LR3 creates.

### Laron Syndrome Evidence

Perhaps the most compelling human data comes from individuals with Laron syndrome — a genetic condition causing IGF-1 receptor deficiency or IGF-1 production failure. These individuals have essentially no functional IGF-1 signaling. Their cancer incidence is dramatically reduced compared to the general population. This represents human genetic proof that IGF-1 signaling contributes to cancer development. When IGF-1 signaling is absent from birth, cancer rates plummet.

This isn't a theoretical concern extrapolated from cell culture experiments. This is epidemiological confirmation in hundreds of thousands of humans, mechanistic validation across decades of oncology research, and genetic proof from populations lacking IGF-1 signaling.

---

## Oncogenesis Risk Assessment - CRITICAL

The cancer risk associated with IGF-1 LR3 operates through well-characterized mechanisms at every stage of oncogenesis.

**Malignant transformation**: The PI3K/Akt pathway, when chronically activated, promotes genetic instability and allows cells with oncogenic mutations to survive when they should undergo apoptosis.

**Tumor growth**: Once a cancer develops, IGF-1R activation drives proliferation through MAPK signaling. Cancer cells often overexpress IGF-1 receptors, making them hyperresponsive to IGF-1 elevation.

**Angiogenesis**: IGF-1 induces VEGF production, promoting blood vessel formation that supplies tumors with nutrients and oxygen. Without angiogenesis, solid tumors cannot grow beyond 1-2mm.

**Invasion and metastasis**: Matrix metalloproteinase (MMP) activation by IGF-1 signaling allows cancer cells to break through basement membranes and invade surrounding tissues — the defining characteristic of malignancy.

**Treatment resistance**: PI3K/Akt activation protects cancer cells from chemotherapy and radiation by enhancing DNA repair and blocking apoptotic pathways that treatments attempt to trigger.

Animal models consistently show that IGF-1 overexpression accelerates aging and reduces lifespan, while reduced IGF-1 secretion delays cancer onset and extends longevity. The EPIC-Heidelberg study confirmed this pattern in humans: both lowest and highest IGF-1 quintiles associated with increased mortality, creating a U-shaped curve where moderate levels optimize both cancer risk and overall survival.

---

## Hypoglycemia Risk

Beyond cancer risk, IGF-1 LR3 presents an acute life-threatening danger: severe hypoglycemia. IGF-1 has significant insulin-like effects, activating insulin receptors and promoting glucose uptake into cells. With LR3's extended half-life and high potency, this can cause blood sugar to crash dangerously low, particularly in fasted states or when combined with exercise.

Symptoms progress from shakiness, weakness, and confusion to seizures and loss of consciousness. This isn't a theoretical risk — it's a documented acute toxicity reported consistently in user forums. The modified structure that enhances anabolic effects also enhances hypoglycemic effects, and the 20-30 hour half-life means a single dose can cause delayed hypoglycemia hours after injection when blood sugar naturally falls between meals or during sleep.

Mandatory precautions include never dosing fasted, always having fast-acting carbohydrates immediately available, starting with the lowest dose, and monitoring blood glucose. Even with precautions, the risk remains substantial.

---

## Use Cases by Goal

Understanding IGF-1 LR3 use cases requires acknowledging that all use is underground and unsupported by human trials. The "benefits" described below come from mechanism-based reasoning and anecdotal reports, not controlled studies.

### Muscle Protein Synthesis Enhancement

The primary purported use involves enhanced muscle growth through direct IGF-1R activation in muscle tissue. The mechanism is sound — IGF-1 activates mTOR and protein synthesis machinery while blocking protein breakdown. Users report improved muscle fullness, accelerated recovery, and enhanced pumps during training.

The reality check: these anecdotal benefits must be weighed against epidemiologically confirmed cancer risk and hypoglycemia danger. No aesthetic benefit justifies these risks.

Conservative protocols suggest 20-40mcg daily for 4 weeks maximum. Standard protocols use 40-80mcg daily for 4-6 weeks. Higher protocols push to 80-120mcg daily for 4 weeks. All dosing comes from bodybuilding sources, not clinical trials.

Administration can be subcutaneous (systemic effect) or intramuscular (potentially localized to injected muscle, though systemic exposure still occurs). Timing typically falls post-workout with carbohydrates to mitigate hypoglycemia risk and provide nutrients for the enhanced anabolic signaling.

### Recovery Acceleration

IGF-1 promotes satellite cell activation and tissue repair, theoretically accelerating recovery between training sessions. Some users report faster healing of training-induced microtrauma and ability to train more frequently.

Again, this lacks controlled evidence and comes with the same cancer and hypoglycemia risks that apply to any use.

### Fat Loss

IGF-1 exerts lipolytic effects, potentially promoting fat oxidation while preserving muscle mass during caloric restriction. This represents the least supported use case, with minimal user evidence and no clinical data.

### Cycling Requirements

All protocols mandate 4-6 week cycles with extended breaks. Continuous use would create perpetual supraphysiological IGF-1 exposure, magnifying both receptor desensitization and cancer risk. Even with cycling, the cumulative oncogenic exposure remains concerning.

---

## Risk Assessment

The risk-benefit calculation for IGF-1 LR3 differs fundamentally from other peptides discussed in this repository. Most peptides present theoretical risks based on mechanism. IGF-1 LR3 presents epidemiologically confirmed cancer risk and documented acute hypoglycemia danger.

Common side effects include lethargy post-injection (transient), joint pain (occasional), and gut/organ growth (dose-dependent). At high doses, acromegaly-like effects can develop — jaw growth, hand enlargement, forehead thickening — representing permanent structural changes from chronic growth factor exposure.

The monitoring protocol reflects the severity of risk. Monthly IGF-1 measurement (not quarterly as with other peptides) ensures rapid detection of supraphysiological elevation. Weekly fasting glucose monitoring captures hypoglycemia patterns and insulin resistance development. Tumor markers (PSA, CEA, CA-125) every 3-6 months provide surveillance for the cancers epidemiologically linked to IGF-1 elevation. Colonoscopy, mammography, and other cancer screening should continue per guidelines and potentially be intensified.

The stop rules are stricter than other peptides. IGF-1 Z-score above 2 standard deviations mandates 50% dose reduction. Z-score above 3 requires immediate discontinuation. Any new mass, lymphadenopathy, or suspicious lesion demands immediate cessation of all growth factors. Significant hypoglycemic episodes contraindicate further use. These aren't negotiable — they represent minimum safety thresholds.

---

## Synergies and Stacking

Stacking IGF-1 LR3 with other growth factors compounds risk without proportional benefit. Combining with GH or GH secretagogues creates redundant IGF-1 elevation — GH raises IGF-1 endogenously, LR3 provides exogenous IGF-1, and the sum creates even higher total IGF-1 exposure.

The only potentially rational stack would involve insulin sensitizers (metformin, berberine) to mitigate glucose dysregulation, but this doesn't address the fundamental cancer risk and may complicate hypoglycemia risk.

The honest assessment: if cancer risk and hypoglycemia danger make IGF-1 LR3 inadvisable as monotherapy, adding other compounds doesn't improve the risk-benefit ratio.

---

## Dosing (Underground/Bodybuilding Context – NOT Trial-Validated)

| Protocol | Dose | Frequency | Duration |
|----------|------|-----------|----------|
| Conservative | 20-40mcg | Daily | 4 weeks max |
| Standard | 40-80mcg | Daily | 4-6 weeks |
| Higher | 80-120mcg | Daily | 4 weeks max |

**Note:** These doses are from bodybuilding sources, not clinical trials. No human efficacy or safety trials exist for these protocols.

**Administration:**
- SC (systemic) or IM (localized to muscle)
- Post-workout timing preferred
- WITH carbohydrates

**Cycling:** 4-6 week cycles mandatory; extended breaks required.

### Purported Benefits (Anecdotal/Underground)

- Enhanced muscle protein synthesis
- Accelerated recovery between workouts
- Improved muscle fullness and pumps
- Possible fat loss (lipolytic effect)

**Reality check:** These claims derive from mechanism-based reasoning and user reports, not controlled human trials. The cancer risk may outweigh any aesthetic benefits.

### IGF-1 Monitoring and Stop Rule

**Target:** Keep serum IGF-1 within age-adjusted upper-normal range (≤1.3× upper limit).

**Stop immediately if:**
- IGF-1 >1.5× upper limit of normal
- Any new mass, lymphadenopathy, or suspicious lesion
- Significant hypoglycemic episode
- Acromegalic symptoms (jaw/hand growth, forehead thickening)

---

## Side Effects

| Effect | Severity | Notes |
|--------|----------|-------|
| Hypoglycemia | HIGH | Can be dangerous |
| Gut/organ growth | MODERATE | Dose-dependent |
| Lethargy post-injection | Common | Transient |
| Joint pain | Occasional | |
| Acromegaly-like effects | At high doses | Dose limitation critical |

---

## Contraindications (Absolute)

- Active or history of cancer
- Family history of IGF-1-associated cancers (colon, breast, prostate)
- Diabetes (hypoglycemia risk)
- Cardiovascular disease
- Age <25 (growth plate concerns)
- Pregnancy/breastfeeding

---

## Monitoring Protocol (If Using)

| Test | Baseline | Ongoing | Rationale |
|------|----------|---------|-----------|
| IGF-1 (with Z-score) | Yes | Monthly | Supraphysiological detection |
| Fasting glucose | Yes | Weekly | Hypoglycemia/IR |
| Fasting insulin | Yes | Every 3 months | Calculate HOMA-IR |
| HbA1c | Yes | Every 3 months | Glucose dysregulation |
| PSA (men >40) | Yes | Every 3-6 months | Prostate surveillance |
| CEA | Yes | Every 6 months | Colorectal marker |
| CA-125 (women) | Yes | Every 6 months | Ovarian surveillance |
| ApoB, Lp(a) | Yes | Every 6-12 months | Cardiovascular risk |
| Cystatin C (if >50) | Yes | Every 6-12 months | Renal function (muscle-independent) |
| Colonoscopy | If due | Per guidelines | Colon cancer screening |
| Mammogram (women) | If due | Per guidelines | Breast cancer screening |

### Action Rules

**IGF-1 Rule (Z-Score Based):**
- Z-score > 2 (>2 standard deviations above mean): **Reduce dose by 50%**
- Z-score > 3: **Discontinue immediately**
- Target: Age-adjusted upper-normal range (≤1.3× upper limit)

**HbA1c Rule:**
- If HbA1c increases >0.5% from baseline OR exceeds 5.7%: **Initiate Metformin 500mg BID or Berberine**

**Tumor Marker Rule:**
- Any elevation in PSA, CEA, or CA-125: **Immediate cessation of ALL growth factors** (GH peptides, BPC-157, TB-500, GHK-Cu, Dihexa, IGF-1 LR3)

**Immediate Stop Criteria:**
- Any new mass, lymphadenopathy, or suspicious lesion
- Significant hypoglycemic episode
- Acromegalic symptoms (jaw/hand growth, forehead thickening)

---

## Comparison

| Compound | Mechanism | Potency | Half-life | Risk Level |
|----------|-----------|---------|-----------|------------|
| IGF-1 LR3 | Direct IGF-1R | Very High | 20-30h | HIGH |
| Native IGF-1 | Direct IGF-1R | Baseline | 15 min | HIGH |
| HGH | GH → IGF-1 | Indirect | Variable | Moderate |
| Ipamorelin | GH release | Indirect | 2h | Lower |

---

## Limitations

1. **Confirmed epidemiological cancer risk** - Not theoretical
2. **No human safety trials** - All data extrapolated
3. **Hypoglycemia can be life-threatening**
4. **Long-term effects unstudied**
5. **Safer alternatives exist** (GH secretagogues)

---

## References

1. Study of ~400,000 confirms IGF-1 cancer risk. Oxford CEU. 2020.
2. IGF-1 and Risk of Morbidity and Mortality. J Clin Endocrinol Metab. 2023.
3. Mechanisms by which IGF-I May Promote Cancer. PMC4164051.
4. LeRoith D, et al. The IGF system and cancer. Cancer Lett. 2003.
5. Francis GL, et al. Novel IGF-I analogs. J Mol Endocrinol. 1992.
